By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) Announces Issuance Of New Patents For Dusquetide 4/14/2016 6:10:23 AM
Soligenix (SNGX) Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease 3/29/2016 6:32:48 AM
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2015 Financial Results 3/24/2016 8:40:48 AM
Soligenix (SNGX) Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine 3/17/2016 6:25:11 AM
Soligenix (SNGX) To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference 2/2/2016 9:41:23 AM
Soligenix (SNGX) Provides 2016 Business Outlook 1/26/2016 7:42:04 AM
Vista Partners Updates Coverage On Soligenix (SNGX) (Ticker: SNGX); Price Target $7.00 12/22/2015 3:45:50 PM
SciClone Pharmaceuticals, Inc. (SCLN) To Pursue Development Of SGX942 In China Following Soligenix (SNGX)' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis 12/21/2015 7:31:40 AM
Soligenix (SNGX) Will Host A Conference Call To Update Shareholders On Recent Positive Clinical Results And Company Development Milestones 12/16/2015 9:25:20 AM
Soligenix (SNGX) Announces Positive Preliminary Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 12/16/2015 6:48:33 AM